BioCryst Pharmaceuticals Inc (BCRX)
4.54
+0.42
(+10.06%)
USD |
NASDAQ |
May 01, 14:12
BioCryst Pharmaceuticals Revenue (Annual): 331.41M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 331.41M |
| December 31, 2022 | 270.83M |
| December 31, 2021 | 157.17M |
| December 31, 2020 | 17.81M |
| December 31, 2019 | 48.84M |
| December 31, 2018 | 20.65M |
| December 31, 2017 | 25.19M |
| December 31, 2016 | 26.35M |
| December 31, 2015 | 48.26M |
| December 31, 2014 | 13.61M |
| December 31, 2013 | 17.33M |
| December 31, 2012 | 26.29M |
| December 31, 2011 | 19.64M |
| December 31, 2010 | 62.38M |
| December 31, 2009 | 74.59M |
| Date | Value |
|---|---|
| December 31, 2008 | 56.56M |
| December 31, 2007 | 71.24M |
| December 31, 2006 | 6.212M |
| December 31, 2005 | 0.1519M |
| December 31, 2004 | 0.3369M |
| December 31, 2003 | 0.6533M |
| December 31, 2002 | |
| December 31, 2001 | 11.16M |
| December 31, 2000 | 3.316M |
| December 31, 1999 | 2.50M |
| December 31, 1998 | 6.40M |
| December 31, 1997 | 1.00M |
| December 31, 1996 | 1.60M |
| December 31, 1995 | 0.20M |
| December 31, 1994 | 0.70M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
17.81M
Minimum
2020
331.41M
Maximum
2023
165.21M
Average
157.17M
Median
2021
Revenue (Annual) Benchmarks
| AIM ImmunoTech Inc | 0.202M |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 65.49M |
| Electromed Inc | 48.07M |
| Armata Pharmaceuticals Inc | -- |